Last reviewed · How we verify
NCT05758675: COVID-19
Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023
trial in COVID-19 in 20,000 participants. Status unknown.
8 September 2023
Quick facts
| Lead sponsor | Sinocelltech Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20,000 |
| Start date | 21 February 2023 |
| Primary completion | 8 September 2023 |
| Estimated completion | 8 December 2023 |
| Sites | 1 location across China |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Sinocelltech Ltd. — full company profile →
Who can join
Adults 3 to 120, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
About 15,000 to 25,000 subjects will be screened. Their information will be collected, venous blood will be sampled, their serum antibody levels will be detected, and the incidence of COVID-19 wil be followed up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05758675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Sinocelltech Ltd. trials
Trials by the same sponsor.
- NCT07244510 — Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa · Phase 2 · not yet recruiting
- NCT07077252 — Phase I/II Study of SCTB39G in Advanced Solid Tumours · Phase 1, PHASE2 · not yet recruiting
- NCT07050641 — Phase I/II Study of SCTB39-1 in Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06769984 — A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. · Phase 1, PHASE2 · not yet recruiting
- NCT06801509 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05758675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinocelltech Ltd.
- Last refreshed: 8 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05758675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing